Australia seems poised to experience innovative therapy for excess weight: Retatrutide. This dual molecule – working on both GLP-1 and GIP receptors – demonstrates promising efficacy in international trials, pointing to meaningful decreases in body fat. While approval remains with the Therapeutic Goods Administration (TGA), several Australians